2020

RPE mutations lead to retinal hypopigmentation, vasculature changes, and decreased function

In their paper, “The microphthalmia-associated transcription factor (Mitf) gene and its role in regulating eye function,” García-Llorca et al use the Phoenix MICRON™ IV to examine the outer eye appearance, retinal pigmentation, and retinal vasculature through fluorescein angiography to study several different mouse mutants. Combined with electroretinography and histology, the fundus images tell a story

2020

Caspase-9 inhibiting eyedrops rescue physiological and functional retinal vein occlusion damage shown with Phoenix MICRON™, OCT, and focal ERG

In a recent well written, compelling article published in Nature Communications, “Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion,” Avrutsky et al show that caspase-9 inhibition is a promising treatment for retinal vein occlusion. Retinal vein occlusion models hypoxic-ischemic neurovascular damage and is the second leading cause of blindness in working-age adults.

2020

Targeting VEGF164 in Müller cells may be useful to treat retinopathy of prematurity

In Nature’s Scientific Reports, Becker et al use the Phoenix MICRON IV, OCT, and focal ERG to assess the therapeutic value of knocking down a splice variant of VEGF in Müller cells in a model of Retinopathy of Prematurity (ROP). ROP is characterized by delayed vascularization of the retina after disrupted oxygen levels, followed by